Association between serum fibroblast growth factor 21 and coronary artery disease in patients with type 2 diabetes

Journal of Korean Medical Science

Volumn 30, Issue 5, 2015, Pages 586-590

  Kim, Won Jin ^a   Kim, Sang Soo ^a   Lee, Han Cheol ^a   Song, Sang Heon ^a   Bae, Min Jung ^b   Yi, Yang Seon ^c   Jeon, Yun Kyung ^a   Kim, Bo Hyun ^a   Kim, Yong Ki ^b   Kim, In Joo ^a  

^a Pusan National University Hospital   (South Korea)

^b Kim Yong Ki Internal Medicine Clinic   (South Korea)

^c Busan Veterans Hospital   (South Korea)

Author keywords

Coronary artery disease; Diabetes mellitus, type 2; Fibroblast growth factor 21

Indexed keywords

FIBROBLAST GROWTH FACTOR; FIBROBLAST GROWTH FACTOR 21;

ADOLESCENT; ADULT; AGED; BLOOD; COMPLICATION; CORONARY ANGIOGRAPHY; CORONARY ARTERY DISEASE; DIABETES MELLITUS, TYPE 2; FEMALE; HUMAN; MALE; MIDDLE AGED; PATHOLOGY; REGRESSION ANALYSIS; SEVERITY OF ILLNESS INDEX; VERY ELDERLY; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; CORONARY ANGIOGRAPHY; CORONARY ARTERY DISEASE; DIABETES MELLITUS, TYPE 2; FEMALE; FIBROBLAST GROWTH FACTORS; HUMANS; MALE; MIDDLE AGED; REGRESSION ANALYSIS; SEVERITY OF ILLNESS INDEX; YOUNG ADULT;

EID: 84951975407     PISSN: 10118934     EISSN: 15986357     Source Type: Journal    
DOI: 10.3346/jkms.2015.30.5.586     Document Type: Article

References (18)

1. Itoh N, Ornitz DM. Evolution of the Fgf and Fgfr gene families. Trends Genet 2004; 20: 563-9.
2. Presta M, Dell'Era P, Mitola S, Moroni E, Ronca R, Rusnati M. Fibroblast growth factor/fibroblast growth factor receptor system in angiogenesis. Cytokine Growth Factor Rev 2005; 16: 159-78.
3. Nishimura T, Nakatake Y, Konishi M, Itoh N. Identification of a novel FGF, FGF-21, preferentially expressed in the liver. Biochim Biophys Acta 2000; 1492: 203-6.
4. Lin Z, Wu Z, Yin X, Liu Y, Yan X, Lin S, Xiao J, Wang X, Feng W, Li X. Serum levels of FGF-21 are increased in coronary heart disease patients and are independently associated with adverse lipid profile. PLoS One 2010; 5: e15534.
5. Kharitonenkov A, Shiyanova TL, Koester A, Ford AM, Micanovic R, Galbreath EJ, Sandusky GE, Hammond LJ, Moyers JS, Owens RA, et al. FGF-21 as a novel metabolic regulator. J Clin Invest 2005; 115: 1627-35.
6. Hojman P, Pedersen M, Nielsen AR, Krogh-Madsen R, Yfanti C, Akerstrom T, Nielsen S, Pedersen BK. Fibroblast growth factor-21 is induced in human skeletal muscles by hyperinsulinemia. Diabetes 2009; 58: 2797-801.
7. Zhang X, Yeung DC, Karpisek M, Stejskal D, Zhou ZG, Liu F, Wong RL, Chow WS, Tso AW, Lam KS, et al. Serum FGF21 levels are increased in obesity and are independently associated with the metabolic syndrome in humans. Diabetes 2008; 57: 1246-53.
8. Li H, Bao Y, Xu A, Pan X, Lu J, Wu H, Lu H, Xiang K, Jia W. Serum fibroblast growth factor 21 is associated with adverse lipid profiles and gamma-glutamyltransferase but not insulin sensitivity in Chinese subjects. J Clin Endocrinol Metab 2009; 94: 2151-6.
9. Mraz M, Bartlova M, Lacinova Z, Michalsky D, Kasalicky M, Haluzikova D, Matoulek M, Dostalova I, Humenanska V, Haluzik M. Serum concentrations and tissue expression of a novel endocrine regulator fibroblast growth factor-21 in patients with type 2 diabetes and obesity. Clin Endocrinol (Oxf) 2009; 71: 369-75.
10. Gensini GG. A more meaningful scoring system for determining the severity of coronary heart disease. Am J Cardiol 1983; 51: 606.
11. Sullivan DR, Marwick TH, Freedman SB. A new method of scoring coronary angiograms to reflect extent of coronary atherosclerosis and improve correlation with major risk factors. Am Heart J 1990; 119: 1262-7.
12. Dostálová I, Haluzíková D, Haluzík M. Fibroblast growth factor 21: a novel metabolic regulator with potential therapeutic properties in obesity/type 2 diabetes mellitus. Physiol Res 2009; 58: 1-7.
13. Badman MK, Pissios P, Kennedy AR, Koukos G, Flier JS, Maratos-Flier E. Hepatic fibroblast growth factor 21 is regulated by PPARalpha and is a key mediator of hepatic lipid metabolism in ketotic states. Cell Metab 2007; 5: 426-37.
14. Inagaki T, Dutchak P, Zhao G, Ding X, Gautron L, Parameswara V, Li Y, Goetz R, Mohammadi M, Esser V, et al. Endocrine regulation of the fasting response by PPARalpha-mediated induction of fibroblast growth factor 21. Cell Metab 2007; 5: 415-25.
15. Seo JA, Kim NH. Fibroblast growth factor 21: a novel metabolic regulator. Diabetes Metab J 2012; 36: 26-8.
16. An SY, Lee MS, Yi SA, Ha ES, Han SJ, Kim HJ, Kim DJ, Lee KW. Serum fibroblast growth factor 21 was elevated in subjects with type 2 diabetes mellitus and was associated with the presence of carotid artery plaques. Diabetes Res Clin Pract 2012; 96: 196-203.
17. Chow WS, Xu A, Woo YC, Tso AW, Cheung SC, Fong CH, Tse HF, Chau MT, Cheung BM, Lam KS. Serum fibroblast growth factor-21 levels are associated with carotid atherosclerosis independent of established cardiovascular risk factors. Arterioscler Thromb Vasc Biol 2013; 33: 2454-9.
18. Lenart-Lipinska M, Matyjaszek-Matuszek B, Gernand W, Nowakowski A, Solski J. Serum fibroblast growth factor 21 is predictive of combined cardiovascular morbidity and mortality in patients with type 2 diabetes at a relatively short-term follow-up. Diabetes Res Clin Pract 2013; 101: 194-200.